{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:45:43Z","timestamp":1793857543103,"version":"4.6.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuropsychiatric (NP) involvement represents one of the major challenges in Systemic Lupus Erythematosus (SLE), often requiring individualized therapeutic strategies. While anifrolumab inhibits the type I interferon receptor 1 (IFNAR1) and is approved for the treatment of moderate-to-severe SLE, randomized controlled trials have not evaluated its efficacy in NPSLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We examined the pathophysiological rationale for inhibiting IFN-\u03b1 using anifrolumab in NPSLE. To supplement this, we report an original case of NPSLE successfully treated with anifrolumab, along with similar cases identified through a systematic literature review (SLR) of Medline\/PubMed and Embase, performed in accordance with PRISMA and CABARET guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overexpression of IFN-\u03b1 is linked to neurological symptoms in patients with inflammatory NPSLE, such as psychosis and seizures. Blocking the IFNAR1 with anifrolumab provides a direct rationale for treating this subset of NPSLE. The SLR identified seven case reports of female patients with inflammatory NPSLE where anifrolumab was used as a rescue therapy following conventional treatment failure. NPSLE manifestations were heterogeneous, including psychosis, headache, and acute confusional state, which limits the generalizability of our findings. A 52-year-old female with SLE and seizures from our Lupus Clinic who received anifrolumab after failing multiple treatments was also reported. After an average of 11.7 months, all patients showed improvement, 87% (7 out 8) achieving complete NP symptom resolution and 62% reaching SLE remission. No emerging safety issues were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Preliminary observations suggest a potential benefit of anifrolumab in NPSLE, but evidence remains insufficient to establish clinical efficacy and warrants further controlled studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1750071","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:55:53Z","timestamp":1770792953000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Rationale for investigating the use of anifrolumab in neuropsychiatric systemic lupus erythematosus: a combined narrative and case-based systematic literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Elisabetta","family":"Chessa","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliera Universitaria (AOU) Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Congiu","sequence":"additional","affiliation":[{"name":"Rheumatology, Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Rheumatology, Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Paola","family":"Pireddu","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliera Universitaria (AOU) Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ragusa","sequence":"additional","affiliation":[{"name":"Rheumatology, Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Floris","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliera Universitaria (AOU) Cagliari","place":["Cagliari, Italy"]},{"name":"Rheumatology, Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliera Universitaria (AOU) Cagliari","place":["Cagliari, Italy"]},{"name":"Rheumatology, Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Piga","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliera Universitaria (AOU) Cagliari","place":["Cagliari, Italy"]},{"name":"Rheumatology, Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/1529-0131","article-title":"The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes","volume":"42","year":"1999","journal-title":"Arthritis Rheum"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa404","article-title":"The management of neuropsychiatric lupus in the 21st century: still so many unmet needs","volume":"59","author":"Govoni","year":"2020","journal-title":"Rheumatol Oxf Engl"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.106351","article-title":"Prospective analysis of neuropsychiatric events in an international disease inception cohort of SLE patients","volume":"69","author":"Hanly","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313512540","article-title":"Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE)","volume":"23","author":"Zirkzee","year":"2014","journal-title":"Lupus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semarthrit.2010.08.001","article-title":"Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis","volume":"41","author":"Unterman","year":"2011","journal-title":"Semin Arthritis Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0156-8","article-title":"Neuropsychiatric lupus: new mechanistic insights and future treatment directions","volume":"15","author":"Schwartz","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/art.40591","article-title":"Review: nervous system disease in systemic lupus erythematosus: current status and future directions","volume":"71","author":"Hanly","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"B8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/rheumatology\/kew341","article-title":"Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement","volume":"56","author":"Cohen","year":"2017","journal-title":"Rheumatol Oxf Engl"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae119","article-title":"Therapeutic strategies and outcomes in neuropsychiatric systemic lupus erythematosus: an international multicentre retrospective study","volume":"63","author":"Bortoluzzi","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120545","article-title":"Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy","volume":"39","author":"Zirkzee","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/rheumatology\/keab324","article-title":"Relevant domains and outcome measurement instruments in neuropsychiatric systemic lupus erythematosus: a systematic literature review","volume":"61","author":"Silvagni","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e225","article-title":"CAse-BAsed REview sTandards (CABARET): considerations for authors, reviewers, and editors","volume":"39","author":"Benlidayi","year":"2024","journal-title":"J Korean Med Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000064","article-title":"Conducting systematic reviews of association (etiology): The Joanna Briggs Institute\u2019s approach","volume":"13","author":"Moola","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1046687","article-title":"Targeting type I interferons in systemic lupus erythematous","volume":"13","author":"Bruera","year":"2023","journal-title":"Front Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25908","article-title":"Absence of neuronal autoantibodies in neuropsychiatric systemic lupus erythematosus","volume":"88","author":"Varley","year":"2020","journal-title":"Ann Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01407-1","article-title":"Juvenile neuropsychiatric systemic lupus erythematosus: identification of novel central neuroinflammation biomarkers","volume":"43","author":"Labouret","year":"2023","journal-title":"J Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13075-025-03539-2","article-title":"The impact of disease activity and interferon-\u03b1 on the nervous system in systemic lupus erythematosus","volume":"27","author":"Zervides","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110983","article-title":"Utility of interferon-\u03b1 as a biomarker in central neuropsychiatric involvement in systemic lupus erythematosus","volume":"39","author":"Fragoso-Loyo","year":"2012","journal-title":"J Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350410","article-title":"Interferon-alpha in lupus psychosis","volume":"35","author":"Shiozawa","year":"1992","journal-title":"Arthritis Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.25","article-title":"IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy","volume":"39","author":"Haroon","year":"2014","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2014.0105","article-title":"Interferon-\u03b1 induces neurotoxicity through activation of the type I receptor and the GluN2A subunit of the NMDA receptor","volume":"35","author":"Kessing","year":"2015","journal-title":"J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2025.110634","article-title":"Type I interferon signaling promotes kainic acid-induced seizures through mTOR activation","volume":"279","author":"Ma","year":"2025","journal-title":"Neuropharmacology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/s0168-8278(96)80185-1","article-title":"Seizures during alpha interferon therapy","volume":"24","author":"Shakil","year":"1996","journal-title":"J Hepatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/0140-6736(90)93356-T","article-title":"Seizures associated with low-dose \u03b1-interferon","volume":"336","author":"Janssen","year":"1990","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13075-019-1985-9","article-title":"Interferon-\u03b1 exacerbates neuropsychiatric phenotypes in lupus-prone mice","volume":"21","author":"Zeng","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201477","article-title":"Anti-IFN-\u03b1\/\u03b2 receptor antibody treatment ameliorates disease in lupus-predisposed mice","volume":"189","author":"Baccala","year":"2012","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319872265","article-title":"Anti-IFNAR treatment does not reverse neuropsychiatric disease in MRL\/lpr lupus mice","volume":"28","author":"Huang","year":"2019","journal-title":"Lupus"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1361_5958","DOI":"10.4049\/jimmunol.212.supp.1361.5958","article-title":"Neurophysiological phenotypes are uncoupled from toll-like receptor (TLR)-mediated systemic disease in a model of Systemic Lupus Erythematosus (SLE)","volume":"212","author":"Stumpf","year":"2024","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e000261","DOI":"10.1136\/lupus-2018-000261","article-title":"Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus","volume":"5","author":"Riggs","year":"2018","journal-title":"Lupus Sci Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007810","article-title":"Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-\u03b1 receptor 1 antibody","volume":"7","author":"Peng","year":"2015","journal-title":"mAbs"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2025.100296","article-title":"Dysregulation of innate and adaptive lymphoid immunity may have implications for symptom attribution and predict responses to targeted therapies in neuropsychiatric systemic lupus erythematosus","volume":"11","author":"Lindblom","year":"2025","journal-title":"J Transl Autoimmun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2025-0390.PV300","article-title":"Experience with anifrolumab in systemic lupus erythematosus patients with neurological manifestations","volume":"52","author":"Gil","year":"2025","journal-title":"J Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2025-0390.PV305","article-title":"Anifrolumab in the management of lupus headaches: A case report","volume":"52","author":"Calabuig","year":"2025","journal-title":"J Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2024.2306053","article-title":"Refractory systemic lupus erythematosus with neuropsychiatric manifestations successfully treated with anifrolumab","volume":"53","author":"Kobayashi","year":"2024","journal-title":"Scand J Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1177\/09612033251314610","article-title":"Chronic inflammatory demyelinating polyneuropathy associated with active systemic lupus erythematous: Anifrolumab as a potentially successful add-on therapy to intravenous immunoglobulins","volume":"34","author":"Marques-Gomes","year":"2025","journal-title":"Lupus"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1157149","article-title":"Brain-reactive autoantibodies in neuropsychiatric systemic lupus erythematosus","volume":"14","author":"Cocco","year":"2023","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2021.02.021","article-title":"Seizures in systemic lupus erythematosus: A scoping review","volume":"86","author":"Rodriguez-Hernandez","year":"2021","journal-title":"Seizure"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0053","article-title":"Anifrolumab in refractory systemic lupus erythematosus: A real-world, multicenter study","volume":"51","author":"Tani","year":"2024","journal-title":"J Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead568","article-title":"Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry","volume":"63","author":"Miyazaki","year":"2024","journal-title":"Rheumatol Oxf Engl"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A5990","article-title":"Alterations in blood-brain barrier permeability in patients with systemic lupus erythematosus","volume":"40","author":"Chi","year":"2019","journal-title":"AJNR Am J Neuroradiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.biopsych.2008.08.010","article-title":"Activation of CNS inflammatory pathways by interferon-alpha: relationship to monoamines and depression","volume":"65","author":"Raison","year":"2009","journal-title":"Biol Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01093-12","article-title":"Visualizing production of beta interferon by astrocytes and microglia in brain of La Crosse virus-infected mice","volume":"86","author":"Kallfass","year":"2012","journal-title":"J Virol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40478-015-0192-4","article-title":"IFN\u03b2 secreted by microglia mediates clearance of myelin debris in CNS autoimmunity","volume":"3","author":"Kocur","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.210.Supp.63.19","article-title":"Interferon-alpha plays an important role in glial-mediated symptoms of neuropsychiatric systemic lupus erythematosus","volume":"210","author":"Lin","year":"2023","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.2.1192","article-title":"Potent induction of IFN-\u03b1 and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus","volume":"182","author":"Santer","year":"2009","journal-title":"J Immunol Baltim Md 1950"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.cell.2024.02.020","article-title":"Type-I-interferon-responsive microglia shape cortical development and behavior","volume":"187","author":"Escoubas","year":"2024","journal-title":"Cell"},{"key":"B49","article-title":"Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin","volume":"34","author":"Katsumata","year":"2007","journal-title":"J Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1177\/096120339200100209","article-title":"Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers","volume":"1","author":"Alcocer-Varela","year":"1992","journal-title":"Lupus"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330506","article-title":"Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement","volume":"33","author":"Hirohata","year":"1990","journal-title":"Arthritis Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041640","article-title":"Raised monocyte chemotactic protein-1 (MCP-1)\/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus","volume":"65","author":"Iikuni","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1177\/096120330000900704","article-title":"Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement","volume":"9","author":"Trysberg","year":"2000","journal-title":"Lupus"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/art.20598","article-title":"Interferon-inducible protein 10\/CXCL10 is increased in the cerebrospinal fluid of patients with central nervous system lupus","volume":"50","author":"Okamoto","year":"2004","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1750071\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:55:54Z","timestamp":1770792954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1750071\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2026.1750071"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1750071","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1750071"}}